OurView Review: Questions to Settle Before Paying for a Compounded GLP-1 Plan

01Who would actually be responsible for your care?

OurView’s role is coordination rather than direct medical practice or pharmacy operation. It says it partners with independent licensed physician networks and a licensed U.S. pharmacy, while independent providers render medical services. The consulted documentation does not identify the clinical networks or individual treating professionals. Before enrolling, ask which organization will conduct your evaluation, who will prescribe, and where you can find that professional’s name and credentials.

The pharmacy relationship needs a separate answer. OurView says a partner compounds and dispenses medication and describes that partner as a licensed, nationwide pharmacy. Those are provider statements, not independent licensing verification in this review. The return policy names Boudreaux’s New Drug Store in Lake Charles, Louisiana, as a return destination, but that does not establish that it dispenses every GLP-1 prescription. Request the actual dispensing pharmacy’s identity before making assumptions about responsibility.

OurView also advertises hormone care for men, hormone and wellness care around menopause, and products including NAD+, Lipo B12 and sermorelin. Those additional offerings establish that the platform is broader than weight management; they do not establish what a GLP-1 plan includes. A useful first conversation should separate platform customer service, prescribing care and pharmacy counseling. Our questions about program fit can help organize those responsibilities without treating a brand name as the entire care team.

02What happens between the free assessment and a prescription?

The advertised process starts with choosing treatment and answering health and treatment questions through a secure patient journey. A licensed provider then reviews eligibility and determines the plan. OurView calls the assessment free, with no commitment or contracts, and estimates that getting started takes about three minutes. That estimate describes beginning the process—not the duration of a consultation, a clinical approval deadline or the time until medication arrives.

The terms reserve a provider’s ability to deny care when it would not be medically or ethically appropriate, including potential misuse. Payment therefore should not be read as approval. Ask when payment information is collected, when a charge occurs and what happens financially if the provider declines treatment. The consulted pages do not establish that sequence or a refund rule for nonprescribing, making a written answer especially useful before choosing a prepaid option.

Access rules also need careful interpretation. The site requires users to be at least 18, while allowing a parent or guardian to use it on a minor’s behalf; that language does not establish pediatric GLP-1 eligibility. Services are intended for residents of the United States and its territories, but no state-by-state availability list is provided. Full clinical criteria, laboratory requirements and consultation format are also unspecified. Ask about your location and the evaluation requirements before assuming you can proceed.

03Which price are you actually agreeing to pay?

OurView provides two payment choices for each advertised compounded medicine. Semaglutide is $109 monthly or $297 prepaid for three months; tirzepatide is $129 monthly or $357 prepaid for three months. The lower $99 and $119 monthly figures are equivalents of quarterly prepayments, not separate monthly-payment offers. Both plans advertise any prescribed dose, no membership fee and free shipping. The site advertises a $30 saving for each three-month option; that is its stated comparison.

The quoted price does not resolve the full purchasing question. The consulted commercial descriptions do not confirm the administration route, concentration, presentation, quantity dispensed or included administration supplies. Nor does a three-month package establish how many containers arrive, how shipments are divided or a minimum treatment commitment. Before paying, request an itemized description of the prescription and services attached to the selected price. Our price questions beyond the monthly figure offer a practical checklist.

OurView attributes its pricing to a direct pharmacy relationship and advertises no price increase for a higher prescribed dose. These statements do not establish a permanent price lock. Its terms say that if a listed price is incorrect, the customer’s alternative is to accept the corrected price or forgo the transaction. The pages also leave renewal dates and advance notices unclear. Confirm the amount collected today, the next billing event and whether ongoing charges require further authorization.

04What exactly would the pharmacy prepare?

The advertised products are compounded semaglutide and compounded tirzepatide, not identified FDA-approved branded products. OurView’s educational material discusses oral and sublingual semaglutide as possibilities to discuss, but that passage does not confirm that those formulations are sold in the advertised plans. Ask the prescriber and pharmacy to identify the exact formulation, administration route and presentation. A medicine’s name alone is not enough to establish what will be dispensed or how the offer compares with another program.

FDA guidance supplies an important distinction: compounded preparations are not FDA approved and do not undergo FDA premarket review for safety, effectiveness and quality. Nonapproval alone does not demonstrate clinical inequivalence or establish a verdict about this platform. FDA recommends compounded drugs for patients whose medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. The consultation should explain the proposed preparation’s role in your care rather than rely on advertising comparisons.

OurView’s terms allow patients to direct a prescription to a pharmacy of their choosing by emailing service@ourviewhealth.com before completing the order. That is a documented choice, but the pages do not establish whether the advertised package price, shipping or other arrangements remain unchanged with an outside pharmacy. Ask first. Also request clear pharmacy instructions rather than attempting measurement calculations yourself; FDA has reported errors measuring or administering compounded medication, some associated with hospitalization.

05Who answers questions after treatment begins?

OurView advertises ongoing dosage adjustments based on a patient’s response, with no extra charge and no extra appointments for those adjustments. It also offers clinical support for medication and progress questions. Those are useful commitments to ask about specifically, but they do not reveal follow-up frequency, business hours, response targets or whether communication is by message, telephone or video. Ask how a clinical concern reaches the prescribing professional and what the advertised adjustment process actually involves.

For order or product problems, the published contact paths are service@ourviewhealth.com and (573) 685-6155. These contacts should not automatically be treated as an urgent clinical service. Ask which channel handles symptoms, pharmacy questions, refill requests and delivery trouble, and what to do outside staffed hours. A concrete escalation process is more useful than a general promise of availability. Our follow-up support questions help distinguish access to customer service from access to clinical judgment.

The terms also describe personalized SMS messages for medication updates, prescription changes, refill reminders and health-related alerts. Texting STOP unsubscribes from that messaging service; it is not described as canceling treatment or billing. OurView warns that email and text are not secure communications and may be read by unauthorized third parties. Ask which patient-portal channel is intended for sensitive clinical information and how notification preferences affect your ability to receive time-sensitive updates.

06What if the shipment is late, missing or unusable?

OurView advertises free shipping, discreet packaging and fast home delivery, but it does not publish a numerical arrival window in the consulted descriptions. There are also no stated timeframes for clinical review, preparation or dispatch. Ask for each stage separately rather than reading “fast shipping” as a promise about the entire process. The available documentation also does not establish transport-storage requirements or the number and timing of shipments within a three-month purchase.

The delivery policy directs patients to contact the care team if medication arrives damaged or is lost in transit. For a lost package, OurView says it will first work with the carrier to locate it and redirect it if needed, and will reship a lost prescription or nonprescription order. That is a more specific remedy than the policy provides for damage: the consulted wording does not state whether damaged medication leads to replacement, refund or another resolution.

If the eventual prescription is an injectable GLP-1 and it arrives warm or with insufficient refrigeration, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. This is not resolved simply by an order being marked delivered. Before shipment, ask whom to contact, what information to retain and how quickly a pharmacy can assess a concern. The important distinction is between delivery tracking, product-condition assessment and a decision about whether a replacement is needed.

07What would cancellation stop—and what would it not undo?

The marketing says there are no contracts and patients can cancel anytime. The operational policy adds a consequential boundary: patients can use patient.ourviewhealth.com before products ship to change an address, update payment details or cancel a subscription. Once payment has been charged and the package handed to the carrier, the policy declares all sales final. Canceling future participation therefore should not be confused with reversing a completed purchase or receiving money back.

Quarterly prepayment makes that distinction particularly important. Public documentation does not explain how unused portions are handled if someone cancels during a three-month plan, nor does it specify automatic-renewal mechanics, next-charge dates or a minimum cancellation notice period. Ask for the applicable cutoff and refund treatment in writing before prepaying. Our questions to settle before the next charge can help turn “cancel anytime” into a specific understanding of future billing and existing payments.

The policy says prescription medicines cannot be returned after dispensing, attributing that restriction to state and federal rules. Separately, it may accept unopened nonprescription returns within 30 days of sale, with return shipping paid by the patient. That nonprescription window is not a GLP-1 refund promise. The terms also reference California law for arbitration in San Diego and Georgia law in a general governing-law clause; clarification is warranted, without drawing a conclusion here about enforceability.

08What should you confirm with your health plan and clinician?

OurView’s services are not health insurance or a substitute for it. More unusually, the ordering terms say patients may not submit claims for the telemedicine services to Medicare, any other federal payer, or a state or private payer. This is a telemedicine-claim restriction, not confirmation of medication coverage or a blanket statement about who may enroll. Medication insurance billing, HSA/FSA acceptance and other payment accommodations remain unconfirmed in the consulted pages.

Ask the program exactly which charges that restriction covers, and ask your health plan separately about medication benefits. NIDDK notes that some plans cover weight-management medicines and others do not; consultation billing and medication coverage are different questions. An answer about one should not be used to fill in the other. OurView’s published package prices provide a starting point for budgeting, but they do not establish insurance reimbursement or eliminate the need to clarify any separate services.

Clinical preparation should be equally concrete. NIDDK advises discussing medicines, supplements, allergies and pregnancy plans, along with health conditions, benefits, side effects and costs. It also emphasizes follow-up for response and tolerability rather than payment renewal alone. Bring those topics to the OurView evaluation and ask how ongoing care will address them. The absence of published eligibility details is a reason to seek a clinician’s explanation, not a basis for predicting either approval or denial.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. OurView — weight loss ↗
4. OurView — return refund policy ↗
5. OurView — official website ↗
6. OurView — terms conditions ↗
7. OurView — weight loss/glp 1 medication comparison/tirzepatide vs semaglutide ↗

Continue reading

• What Does a GLP-1 Program Need to Explain Before You Enroll?
• Ten GLP-1 Price Questions Beyond “How Much per Month?”
• Who Can Answer Your Questions After the First GLP-1 Prescription?
• Questions to Settle Before the Next GLP-1 Program Charge